Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Edgewise news feed on Stock Titan aggregates company announcements, press releases, and other coverage related to its clinical programs, corporate developments, and financial updates.
Investors and observers following EWTX news will see regular updates on the company’s lead product candidates. These include sevasemten, an orally administered first-in-class fast skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophies; EDG-7500, a cardiac sarcomere modulator in Phase 2 development for hypertrophic cardiomyopathy; and EDG-15400, a cardiac sarcomere modulator in Phase 1 development for heart failure. News items often describe trial progress, such as enrollment status, interim results, and plans for pivotal studies, as well as interactions with regulators.
The Edgewise news stream also features corporate and governance updates, including board and executive appointments, inducement equity grants under Nasdaq Listing Rules, participation in major healthcare and investor conferences, and periodic financial results. These disclosures provide context on how the company is building its organization and funding its research and development activities.
By monitoring this page, readers can review historical and recent EWTX news related to muscular dystrophy and cardiovascular programs, clinical milestones, and corporate actions as reported by the company in its public communications.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity awards on November 3, 2025. On October 31, 2025, the company granted inducement stock options to purchase 170,750 shares to seven new non-executive employees under the 2024 Inducement Equity Incentive Plan.
Each option has an exercise price of $18.28 (equal to the closing price on the grant date). Vesting is 25% after one year, then 1/48th monthly thereafter, subject to continued service. Awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) announced on October 2, 2025 that it granted inducement awards on September 30, 2025 to nine new non-executive employees under its 2024 Inducement Equity Incentive Plan.
The grants consist of 247,000 stock options with an exercise price of $16.22 (equal to the closing price on the grant date) and 15,000 RSUs. Options vest 25% after one year then monthly over 3 years; RSUs vest 1/4 annually over four years. Awards were granted as inducements per Nasdaq Rule 5635(c)(4).
Edgewise Therapeutics (NASDAQ:EWTX) will present key findings on sevasemten, their oral treatment for Becker and Duchenne muscular dystrophies, at the 30th International Annual Congress of the World Muscle Society in Vienna, Austria (October 7-11, 2025).
The company will host a symposium on October 8, 2025, featuring presentations from key opinion leaders discussing natural history insights and clinical progress. Three scientific posters will be presented on October 10, highlighting results from the CANYON trial in Becker muscular dystrophy, trajectory data compared to natural history, and LYNX Phase 2 trial results in DMD that will inform Phase 3 design.
Edgewise Therapeutics (Nasdaq: EWTX), a biopharmaceutical company focused on muscle diseases, has granted inducement stock options to 2 new non-executive employees. The options allow the purchase of 16,500 shares at an exercise price of $14.35 per share, matching the closing price on the grant date of August 29, 2025.
The options, granted under the company's 2024 Inducement Equity Incentive Plan, will vest over four years, with 25% vesting after one year and the remaining vesting monthly at a rate of 1/48th, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 2025 financial results and clinical progress. The company announced positive top-line data from multiple trials of sevasemten in muscular dystrophy patients. Key highlights include 99% enrollment in the MESA open-label extension trial for Becker muscular dystrophy, showing sustained disease stabilization over 18 months.
The company completed enrollment of 175 adults in the GRAND CANYON pivotal trial, with topline data expected in Q4 2026. For Duchenne muscular dystrophy, encouraging results were reported from the LYNX and FOX Phase 2 trials. Additionally, Edgewise is advancing its CIRRUS-HCM Phase 2 trial of EDG-7500 for Hypertrophic Cardiomyopathy.
Financially, Edgewise maintains a strong position with $594.0 million in cash and equivalents. Q2 2025 R&D expenses were $33.6 million, down from $36.8 million in Q1, with a net loss of $36.1 million ($0.34 per share).
Edgewise Therapeutics (NASDAQ: EWTX), a biopharmaceutical company focused on muscle diseases, has granted equity-based inducement awards to 3 new non-executive employees. The awards include 84,250 stock options with an exercise price of $14.26 per share and 5,000 restricted stock units (RSUs).
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments starting July 31, 2025. These awards were granted under the company's 2024 Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (NASDAQ:EWTX) reported positive results for sevasemten in treating Becker and Duchenne muscular dystrophies. The MESA open-label trial showed sustained disease stabilization for up to three years in Becker patients, with a 0.8-point improvement in NSAA scores over 18 months.
Following a successful FDA Type C meeting, the company received clarity on the registration path for sevasemten as the first-ever Becker therapy. The GRAND CANYON pivotal trial is progressing toward topline data in Q4 2026. Additionally, Phase 2 trials (LYNX and FOX) in Duchenne patients identified 10 mg as the optimal dose for Phase 3, with plans to initiate the pivotal study in 2026.
Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation in the RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for Tuesday, May 20, 2025, at 9:00 am ET. The event will feature a live webcast accessible through the company's Events & Presentations page, with replay availability for a limited time after the conference. Attendees are advised to connect several minutes before the start time to ensure proper connection.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
